Drug-Coated Chocolate PTA Balloon in Patients With Peripheral Arterial Disease - The ENDURE Trial

Peripheral Vascular Disease Clinical Trial

— ENDURE  

Official title:

First in Human Evaluation of the Drug-Coated Chocolate Balloon for Percutaneous Transluminal Revascularization of Infrainguinal Arterial Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02129127
• Other study ID #: CLP004
• Status: Completed
• Phase: N/A
• First received: April 30, 2014
• Last updated: April 12, 2017
• Start date: March 2014
• Est. completion date: April 2017

Study information

• Verified date: April 2017
• Source: TriReme Medical, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This first-in-man study is to evaluate the Drug-Coated Chocolate (DCC) Balloon for percutaneous arterial angioplasty in patients with symptomatic peripheral arterial disease. The study focuses on acute device performance and peri-procedural safety and also seeks to further characterize the performance of the device.

Description:

This is a prospective, multi-center, single-arm study. Symptomatic lower extremity Peripheral Arterial Disease (PAD) patients presenting for endovascular revascularization will be enrolled in the study if they meet all entry criteria. The study will include patients from New Zealand and the European Union. The endpoints were designed to establish safety of the DCC and to identify long-term clinical benefits of this technology.

The patients treated in this study will be designated into the above the knee (ATK) follow-up schedule if they are treated with the DCC in the SFA or Popliteal vessels. This schedule calls for clinical visits with duplex ultrasounds at 1,6 and 12 months. Patients will be designated into the below the knee (BTK) follow-up schedule if they are treated with the DCC in the Peroneal, Anterior Tibial, Posterior Tibial or Pedal vessels. These patients will have clinical visits at 1, 3 and 6 months with duplex ultrasound at the 1 and 6 months visits only.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 67
• Est. completion date: April 2017
• Est. primary completion date: June 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria:

• Intermittent claudication or critical limb ischemia

• Atherosclerotic target lesion >70% stenosis

• Reference vessel diameter (RVD) between 2.0 and 6.0mm

• Angiographic evidence of distal run-off

• Target lesion length <150mm that consists of no more than two adjacent lesions( < 25mm apart) and is able to be completely covered with inflation of no more than two DCC devices

Key Exclusion Criteria:

• Acute limb ischemia or thrombolytic therapy

• Known and relevant allergies/hypersensitivities

• Known impaired renal function

• Known bleeding disorder

• Severe calcification at the target lesion

• Previous bypass or stent at, or proximal to, target vessel

• Aneurysm in target limb

• Prior major limb amputation

• Use of a any of the following: re-entry device, atherectomy, laser or other ablation procedure, or cutting/scoring balloon at the target lesion; use of drug eluting stent, or non-study drug coated balloon in the target limb.

Related Conditions & MeSH terms

• Peripheral Arterial Disease
• Peripheral Vascular Disease
• Peripheral Vascular Diseases
• Vascular Diseases

Intervention

Device:
• Paclitaxel Coated Chocolate Balloon Angioplasty
Balloon Angioplasty with the Chocolate Balloon resulting in vessel dilatation and localized delivery of Paclitaxel

Locations

Country	Name	City	State
Germany	Universitats Herzzentrum Bad Krozingen	Bad Krozingen
New Zealand	Auckland City Hospital	Auckland

Sponsors (1)

Lead Sponsor	Collaborator
TriReme Medical, LLC

Countries where clinical trial is conducted

Germany,  New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Late Lumen Loss (LLL)	LLL is determined by assessing the difference between the minimum lumen diameter (MLD) immediately after treatment with the DCC and the MLD at angiographic follow-up. LLL will determined by the Angiographic Core Laboratory.	3 Months (BTK) or 6 Months (ATK)
Secondary	Device Success	This is defined as the percentage of procedures that accomplish less than 30% residual stenosis without flow-limiting dissection at target lesion after DCC treatment.	approx 1 hour
Secondary	Technical Success	This is defined as the percentage of cases in which the DCC is able to be delivered to and inflated at the intended target lesion location successfully.	approx 1 hour
Secondary	Device Related Adverse Events (AEs)	Occurrence and Severity of any DCC Related AEs will be analyzed	30 days
Secondary	Freedom from Target Lesion Revascularization (TLR)	This will calculate the number of patients who do not require a clinically indicated TLR. Clinically indicated TLR is defined as any repeat percutaneous intervention at the DCC target lesion or bypass surgery at the DCC target vessel performed for >50% restenosis or another complication of the target lesion	30 days / 3 Months (BTK only) / 6 Months / 12 Months (ATK only)
Secondary	Amputation Free Survival	This is a composite endpoint which counts the number of patients who experience limb salvage. Patients will fail this endpoint if they undergo a major amputation (defined as unplanned amputation at or above the ankle) or if a procedure related death occurs.	30 days / 3 Months (BTK only) / 6 Months / 12 Months (ATK only)
Secondary	Patency	The percentage of cases in which the treated lesion is patent. Patency is demonstrated by a Peak Systolic Velocity ratio <2.5 at the target lesion assessed on Duplex Ultrasound without the need for re-intervention.	6 Months / 12 Months (ATK only)